Evidence map›Paper›PMID 37665491›Full record

ReviewTargeted oncology2023

Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.

Jiayu Wang, Dana Al-Majid, J Chad Brenner, Joshua D Smith

Abstract readReview
PubMed Publisher
In one paragraph

Review in Targeted oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jiayu WangDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA.
Dana Al-MajidDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, MSRB III 1150 W. Medical Center Dr., Ann Arbor, MI, 48109, USA.
J Chad BrennerDepartment of Pharmacology, University of Michigan, Ann Arbor, MI, 48109, USA. chadbren@med.umich.edu.ORCID 0000-0003-3238-1111
Joshua D SmithDepartment of Otolaryngology-Head and Neck Surgery, University of Michigan, MSRB III 1150 W. Medical Center Dr., Ann Arbor, MI, 48109, USA.
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
Robust Immuno-prevention Strategies for High-Risk Oral Epithelial DysplasiaU01DE029255 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BRENNER, JOHN CHADWICK, LEI, YU LEO · 2019 to 2021
$4.2M
NCI NIH HHS P30CA046592NIDCR NIH HHS U01 DE029255
6 · The paper itself

Abstract

Head and neck squamous cell carcinomas (HNSCCs) are often associated with poor outcomes, due at least in part to the limited number of treatment options available for those patients who develop recurrent and/or metastatic disease (R/M HNSCC). Even with the recent validation and approval of immunotherapies in the first-line setting for these patients, the need for the development of new and alternative precision medicine strategies with survival benefit is clear. Oncogenic alterations in the HRAS (Harvey rat sarcoma virus) proto-oncogene are seen in approximately 4-8% of R/M HNSCC tumors. Recently, several preclinical and clinical advancements have been made in the implementation of small-molecule inhibitors that block post-translational farnesylation of HRas, thereby abrogating its downstream oncogenic activity. In this review, we focus on the biology of wild-type and mutant HRas signaling in HNSCC, and rationale for use and outcomes of farnesyltransferase inhibitors in patients with HRAS-mutant tumors.

Indexed as

Head and Neck NeoplasmsProto-Oncogene Proteins p21(ras)Enzyme InhibitorsFarnesyltranstransferaseHumansKidneySignal TransductionSquamous Cell Carcinoma of Head and NeckUrogenital AbnormalitiesEnzyme InhibitorsFarnesyltranstransferaseHRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID37665491
OpenAlexW4386407871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.